COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Endometrial Neoplasms · Ovarian Cancer · Solid Tumor · Head and Neck Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due May 2024, none posted yet
Counts until it's fixed
Score over time
- Stage
- Phase 1/2
- Patients
- 48 (final count)
- Started
- Aug 31, 2020
- Main results expected
- May 15, 2024
- Fully finished
- May 15, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The proportion of subjects with adverse events on the study.
Measured over: 2 years.
The proportion of subjects with adverse events in the 1st cycle during dose escalation within the DLT window (28 days).
Measured over: Within the DLT window (1st 28 days) of the 1st cycle during dose escalation.
The recommended dose for expansion (RDFE) of the combination.
Measured over: 2 years.
The Area under the curve of COM701 in subjects receiving the 3-drug combination.
Measured over: 2 years.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-05-15, no fading
Raw record changes
- none yet
Trial ID NCT04570839 · record last updated 2024-07-18 · checked 2026-11-09 15:47 UTC